Today, Blood Advances published a study revealing that patients with relapsed/refractory (r/r) lymphoma during pregnancy experienced a progression-free survival rate of 24% and an overall survival rate of 83%. Read More
Andrew Evens, DO, MBA, MSc, associate director for clinical services at Rutgers Cancer Institute of New Jersey and system director of medical oncology and oncology lead at RWJBarnabas